Spots Global Cancer Trial Database for Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
Official Title: A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders
Study ID: NCT00992732
Study Description
Brief Summary: The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.
Detailed Description:
Keywords
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
LPCH/Stanford, Palo Alto, California, United States
University of California, San Francisco, San Francisco, California, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Washington University School of Medicine, St. Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Weill Cornell Medical College, New York, New York, United States
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Feigin Center - Center for Cell and Gene Therapy, Houston, Texas, United States
Contact Details
Name: Ron Berenson, MD
Affiliation: HemaQuest Pharmaceuticals Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
